Free Trial
NYSE:MTNB

Matinas Biopharma (MTNB) Stock Price, News & Analysis

Matinas Biopharma logo
$0.56 -0.01 (-2.02%)
Closing price 03:56 PM Eastern
Extended Trading
$0.55 -0.01 (-2.06%)
As of 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Matinas Biopharma Stock (NYSE:MTNB)

Key Stats

Today's Range
$0.52
$0.57
50-Day Range
$0.52
$0.66
52-Week Range
$0.48
$13.95
Volume
19,343 shs
Average Volume
181,598 shs
Market Capitalization
$2.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Remove Ads
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

Matinas BioPharma appoints Murphy, Neugeboren to board of directors
Partner with Elon Musk on Project Colossus… Before May 1st
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Matinas BioPharma appoints Evelyn D’An to board of directors
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas Biopharma's stock was trading at $0.51 on January 1st, 2025. Since then, MTNB shares have increased by 9.5% and is now trading at $0.5585.
View the best growth stocks for 2025 here
.

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02).

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

Last Earnings
8/14/2024
Today
4/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MTNB
Previous Symbol
NYSE:MTNB
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million
Price / Cash Flow
N/A
Book Value
$4.43 per share
Price / Book
0.13

Miscellaneous

Free Float
4,599,000
Market Cap
$2.84 million
Optionable
N/A
Beta
1.53
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:MTNB) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners